芬吗通在行冻融周期胚胎移植子宫内膜发育不良患者中的应用

目的谈论芬吗通在行冻融周期胚胎移植子宫内膜发育不良患者中的应用方法48例子宫内膜发育不良患者给予芬吗通激素替代治疗方案治疗，对完成移植周期的38例患者根据是否着床成功分为着床组和未着床组，比较两组一般资料和用药后子宫内膜厚度的变化情况。结果两组患者年龄、周期前内膜厚度等一般资料差异无统计学意义。着床组用药后9 d和移植日内膜厚度均要大于未着床组，但两组差异比较无统计学意义(P>0.05)；着床组要内膜增加厚度大于未着床组，同时差异具统计学意义(P<0.05)。结论内膜增加厚度可能是影像着床成功率的重要因素之一，而芬吗通在促进子宫内膜发育不良患者内膜容受性改变方面效果较为理想。 

Femonston frozen thawed embryo transfer cycles in patients with poor endometrial development in application

Objective To talk about femonston frozen thawed embryo transfer cycles in patients with poor endometrial development in application. Methods 48 cases of endometrial dysplasia patients given femonston hormone replacement therapy regimens in the treatment of 38 cases of transplantation, complete cycle of patients according to whether the implantation success divided into implantation group and the non implantation group, changes of endometrial thickness were compared between the two groups after administration of general information and. Results The general data such as endometrial thickness was no significant difference between two groups of patients with age, the cycle before. 9 days after the implantation of medication group and transplantation on endometrial thickness were greater than non implantation group, but no significant difference between two groups (P>0.05); endometrial implantation group to increase the thickness is greater than the non implantation group, with statistically significant difference (P<0.05). Conclusion Endometrial thickness increase may be an important factor in image implantation success rate, but with femonston in promoting endometrial dysplasia in patients with endometrial receptivity to change aspects of ideal effect.